Results 211 to 220 of about 10,662,454 (348)

BCOR gene alterations in hematologic diseases.

Blood, 2021
Sportoletti P, Sorcini D, Falini B.
europepmc   +1 more source

Erythrocyte Antibodies in AIDS are associated with mycobacteriosis and hypergammaglobulinemia [PDF]

, 1990
A. Matuschke, AP Rapoport, B. Gathof, B. Heinrich, F. -D. Goebel, FJ Raal, J Lelie van der, J. R. Bogner, L Morris, LI Zon, LI Zon, M Adams, MH McGinniss, P Zauber, PT Toy, PT Toy, PY Lepennec, R Perricone, U. Bäcker, V Daniel, Y Inada, Y Schoenfeld   +21 more
core   +1 more source

In vitro modeling of the microvascular occlusion and thrombosis that occur in hematologic diseases using microfluidic technology.

Journal of Clinical Investigation, 2012
Michelle Z Tsai, Ashley Kita, J. Leach, Ross W S Rounsevell, James N. Huang, J. Moake, R. Ware, D. Fletcher, W. Lam   +8 more
semanticscholar   +1 more source

DCAF13 Safeguards Hematopoietic Stem Cells via RRS1‐Regulated Ribosome Biogenesis

Advanced Science, EarlyView.
This study establishes DCAF13 as an essential regulator for hematopoietic stem cell (HSC) function. Its deletion in mice causes lethal pancytopenia and HSC depletion. Mechanistically, DCAF13 interacts with RRS1 and mediates its non‐degradative K27‐linked ubiquitination, thereby stabilizing RRS1 to maintain ribosome biogenesis and protein translation ...
Mengke Li, Yuxin Wu, Shuai Zhou, Peipei Tang, Jiaming Wei, Ling Liu, Zhenyi Wang, Deyang Shi, Shengnan Yuan, Qingyu Zhang, Shihui Wang, Qing Zhang, Huan Zhao, Rui Zhang, Yingying Wang, Shiwei Yang, Xiangli Chen, Xiaojing Shi, Guangzhi Liu, Yuwei Zhang, Jinming Li, Xu Dong Zhang, Rick F Thorne, Dongping Wei, Zumin Zhu, Song Chen   +25 more
wiley   +1 more source

Clinical outcomes of patients with lymphoid blastic phase of chronic myeloid leukemia treated with CAR T-cell therapy

Blood Cancer Journal
Yujie Liu, Yuqing Tu, Jinyan Xiao, Yifan Shen, Biqi Zhou, Qiannan Yang, Lei Yu, Lijuan Qi, Jia Chen, Tianhui Liu, Depei Wu, Yang Xu   +11 more
doaj   +1 more source

Expert consensus on the off-label use in China of drugs for rare hematologic diseases (2024 edition). [PDF]

Front Pharmacol
Zhao B, Zhou X, Zheng P, Zhang B, Feng X, Chen J, Cai L, Chen Y, He L, Su J, Cheng S, Zeng Y, Li G, Ji B, Wu J, Feng W, Liu M, Jin Y, Liu T, Mo X, Wu J, Wu H, Zhang H, Zheng Z, Zheng Z, Sun J, Li Y, Guangdong Pharmaceutical Association, Hematology Group of Rare Disease Expert Committee of Guangdong Pharmaceutical Association.   +28 more
europepmc   +1 more source

Discovery of H2 Receptor Antagonists as Colistin Enhancers by Targeting Acid Stress Response

Advanced Science, EarlyView.
This study identifies YqgB as a key target for restoring colistin susceptibility in mcr‐positive pathogens under acidic conditions by remodeling phospholipid composition and reducing LPS modification. Deep learning‐based screening reveals H2 receptor antagonists as novel colistin adjuvants. Further investigations indicate that ranitidine and famotidine
Jinju Cai, Mengping He, Jianya Luo, Shuang Zhou, Tengyue Zhang, Jianing Li, Zhiqiang Wang, Yuan Liu   +7 more
wiley   +1 more source

CEBPA double mutations associated with ABO antigen weakness in hematologic diseases. [PDF]

Blood Adv
Choi SJ, Kim HK, Suh EJ, Kwon SS, Shin S, Lee ST, Kim S.   +6 more
europepmc   +1 more source

Improved Systemic Immunochemotherapy Employing an Oxaliplatin‐TLR7/8 Agonist Prodrug Strategy

Advanced Science, EarlyView.
A platinum(IV) prodrug is developed to systemically deliver the TLR7/8 agonist gardiquimod. Tumor‐targeting is mediated by an albumin‐binding maleimide, which limits premature complex activation. Ox‐Gardi‐Mal accumulates specifically in the tumor, where it activates the immune system.
Michael Gutmann, Martijn Dijkstra, Philipp Salomon, Jamie Cowles, Anja Federa, Dina Baier, Carola Jaunecker, Iemima Semerean, Venla Karvonen, Christine Pirker, Maria Sibilia, Dietmar Herndler‐Brandstetter, Petra Heffeter, Bernhard K. Keppler, Christian R. Kowol, Walter Berger   +15 more
wiley   +1 more source